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Bronchoalveolar lavage (BAL) has been a useful initial diagnostic tool in the evaluation of pulmonary com-
plications after hematopoietic stem cell transplantation (HSCT); however, the diagnostic sensitivity, preva-
lence, and outcome after BAL versus lung biopsy (LB) in pediatric HSCT patients remains to be determined.
We reviewed 193 pediatric HSCT recipients who underwent a total of 235 HSCTs. Sixty-ﬁve patients (34%)
underwent a total of 101 BALs for fever, respiratory distress, and/or pulmonary inﬁltrates on chest radiograph
and/or computed tomography scan. The 1-year probability of undergoing BAL was 43.0% after allogeneic stem
cell transplantation (alloSCT) and 8.5% after autologous stem cell transplantation (autoSCT) (P ¼ .001). Sixteen
of the 193 patients (8%) patients underwent 19 LBs. The probability of undergoing LB at 1 year after HSCT was
9.3%. No grade III or IV adverse events related to either procedure were observed. Of the 101 BALs performed,
40% (n ¼ 40) were diagnostic, with a majority revealing a bacterial pathogen. Among the 19 LBs performed,
94% identiﬁed an etiology. In multivariate analysis, myeloablative conditioning alloSCT conferred the highest
risk of requiring a BAL (hazard ratio [HR],8.5; P ¼ .0002). The probability of 2-year overall survival was 20.2%
in patients who underwent BAL, 17.5% for patients who underwent biopsy, and 67.4% for patients who had
neither procedure. In multivariate analysis, only the requirement of a BAL was independently associated with
an increased risk of mortality (HR, 2.96; P < .0001). In summary, in this cohort of pediatric HSCT recipients,
BAL and LB were used in approximately 35% and 8% of pediatric HSCTs with diagnostic yields of approxi-
mately 40% and 94%, respectively, and were both associated with poor long-term outcomes.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION diagnosis has been shown to be a negative prognostic factor
Pulmonary complications have been reported in approx-
imately 25% of pediatric recipients after hematopoietic stem
cell transplantation (HSCT) [1]. Infectious etiologies are the
most prevalent causes of pulmonary dysfunction after HSCT
[2]. Early pulmonary complications have been associated
with a signiﬁcantly decreased overall survival in children
after allogeneic HSCT (alloSCT) [3]. HSCT recipients who
present with clinical and radiological ﬁndings of pulmonary
inﬁltrates often receive empiric broad-spectrum antimicro-
bial therapy [4]. However, a delay in establishing a deﬁnitivedgments on page 1236.
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14.04.019in immunocompromised patients [4,5]. To establish an
earlier, more deﬁnitive diagnosis, bronchoalveolar lavage
(BAL) is regarded as an initial diagnostic tool in pediatric
immunocompromised patients with pulmonary dysfunction
[6]. However, the diagnostic yield of BAL in pediatric HSCT
recipients has been reported as varying from 29% to 68%,
with a reduced yield in those patients with grade II to IV
graft-versus-host disease (GVHD) and in those receiving
immunosuppressive therapy [7,8]. It has been suggested that
some of this variation could result from the procedure’s
timing, with higher diagnostic yield and favorable impact on
survival resulting from early use of BAL, but this requires
further investigation [9].
In the absence of deﬁnitive ﬁndings from BAL, many pa-
tients continue to receive empiric antimicrobial treatments
that can have deleterious toxicities, including but not limited
to ototoxicity, renal insufﬁciency, and hepatotoxicity [10,11].Transplantation.
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in HSCT recipients may indicate noninfectious processes,
including GVHD, disease recurrence, and treatment/
transplantation-associated toxicity [12].
After HSCT, children are also at risk for a variety of
noninfectious pulmonary complications, which are unlikely
to be diagnosed after a BAL, including GVHD, idiopathic
pneumonia syndrome, and interstitial ﬁbrosis [13-15]. Lung
biopsy (LB) can have an increased diagnostic yield, given its
ability to detect infectious and noninfectious etiologies. The
diagnostic sensitivity of LB has been reported to be 60% to
100% in patients with pulmonary complications after HSCT
[13-15]. However, diagnosis based on LB specimens has been
reported to be less sensitive in immunocompromised chil-
dren [14,16-18]. Additionally, the reported complication rates
in children after open LB (OLB) vary widely, from 2% to 52%,
depending on the patients’ underlying disease and degree of
immunocompromise [17].
The impact of LB on overall survival has not yet been
prospectively evaluated. In retrospective studies of pediatric
populations, LB led to a speciﬁc diagnosis in most cases, with
the most common organisms recovered being cytomegalo-
virus (CMV) and Aspergillus fumigatus; the overall mortality
after LB ranged from 24% to 45% [13-15]. Single-institution
experience demonstrated that OLB was very effective at
identifying pulmonary pathology in pediatric HSCT re-
cipients but had little impact on mortality. OLB identiﬁed
noninfectious causes in 58% of the cases and an infectious
organism in 30% of cases; postoperative complications were
reported in 47% of patients [9].
Reduced-toxicity conditioning (RTC) has recently been
employed in children before allogeneic HSCT, as we have pre-
viously reported [19-23]. Although this approach may reduce
earlymortality, there seems tobesimilar riskofviral and fungal
infections compared with those receiving myeloablative con-
ditioning (MAC) [21]. However, there have been no reported
studies that evaluated the impact of pulmonary complications
comparing MAC or RTC in pediatric HSCT recipients. Further-
more, there is a paucity of information reporting the safety and
effectiveness of video-assisted thorascopy (VAT) or computed
tomography (CT)eguided biopsy in pediatric HSCT recipients.
Therefore, in the current study, we examined the diagnostic
yield of BAL and LB, including OLB, VATs, and CT-guided
biopsies, and also compared the survival of children with
pulmonary complications after autologous and allogeneic
HSCT with either prior RTC or MAC.
METHODS
Patients
We evaluated the safety and efﬁcacy of BAL and LB in 193 consecutive
children and adolescents who underwent HSCT at New York-Presbyterian
Morgan Stanley Children’s Hospital. Patients received MAC or RTC before
allogeneic transplantation (MAC alloSCT, RTC alloSCT) or MAC before
autologous transplantation (MAC autoSCT). All patients were enrolled on
institutional review boardeapproved research protocols and parents and/
or patients signed informed consent, as applicable, before to the initiation
of therapy. All research was conducted in compliance with the Declaration
of Helsinki. The following studies were registered with clinicaltrials.gov:
NCT00669890, NCT01050439, NCT00802113, NCT00408447. This retro-
spective study was approved by the institutional review board of Columbia
University Medical Center.
Conditioning Regimens
Conditioning regimens were largely protocol driven and disease spe-
ciﬁc, and they consisted of both MAC (n ¼ 172, 63%) and RTC (n ¼ 72, 37%).
Most MAC regimens consisted of total body irradiation (TBI, 1200 cGy) or
busulfan (12.8 mg/kg in patients > 4 years of age, 16 mg/kg in
patients  4 years of age) in combination with melphalan (135 mg/m2) orcyclophosphamide as follows: TBI/melphalan, TBI/cyclophosphamide,
busulfan/cyclophosphamide, or busulfan/melphalan. Lung shielding was
not used for TBI-containing regimens. Busulfan-containing conditioning
regimens utilized busulfan pharmacokinetic dose adjustment and were
targeted to achieve 600 to 900 ng/mL steady-state concentration, as we
have previously reported [20,23]. RTC regimens were ﬂudarabine-based
(150 to 180 mg/m2) as follows: ﬂudarabine/busulfan (12.8 mg/kg in
patients > 4 years of age, 16 mg/kg in patients  4 years of age) and ﬂu-
darabine/cyclophosphamide, as we have previously reported [23]. Many
patients also received rabbit antithymocyte globulin or alemtuzumab as
part of RTC prior to AlloSCT [19].
Cell Sources, HLA Typing, and Donor Chimerism Studies
Grafts were from unrelated and related donors, with cell sources of bone
marrow, peripheral blood stem cells, or cord blood. HLA typing was per-
formed, and transplantations were classiﬁed as fully matched or HLA-
mismatched with 1 or 2 differences, as we previously described [19,24,25].
GVHD Prophylaxis
Acute GVHD (aGVHD) prophylaxis consisted of tacrolimus and myco-
phenolate mofetil (MMF). Tacrolimus was administered starting at .03 mg/
kg per day as continuous i.v. infusion or .12 mg/kg orally (PO) twice a day,
with dosage adjustment to maintain blood levels between 5 and 20 ng/mL,
starting on the ﬁrst day of conditioning regimen or 1 day before trans-
plantation (day 1), as we have previously reported [26,27]. MMF was
administered at 15 to 30 mg/kg every 6 to 12 hours, either PO or i.v., starting
the day after transplantation (day þ1), as we have previously described
[26,27]. For sibling donor transplant recipients, at day þ30, MMF was
stopped and tacrolimus was weaned over a 4 to 8 week period if patients
had  grade II aGVHD. For unrelated donor transplant recipients, MMF was
stopped at day þ30 and tacrolimus was continued until day þ60, when it
was weaned over a 4 to 8 week period, if patients had  grade II aGVHD
[26,27]. Acute GVHD and chronic GVHD (cGVHD) were graded according to
Seattle consensus criteria [28]. All patients who achieved any level of donor
chimerism were considered at risk for developing aGVHD. Only patients
with sustained engraftment of donor hematopoiesis and surviving for more
than 100 days after transplantation were evaluated for the development of
cGVHD.
Supportive Care
Infectious disease prophylaxis consisted of the following: herpes sim-
plex virus prophylaxis (from day 5 until neutrophil engraftment with
acyclovir 250 mg/m2/dose i.v., every 8 hours), antifungal prophylaxis from
day 0 to day 100with liposomal amphotericin B 3mg/kg i.v. daily as we have
previously reported [29], Pneumocystis jirovecii prophylaxis (beginning
when absolute neutrophil count (ANC)  500/mm3  2 days after trans-
plantation) with trimethoprim sulfamethoxazole (TMP/SMX) 5 mg/kg/day
PO divided twice daily thrice weekly or pentamidine 4 mg/kg i.v. every
2 weeks for patients unable to tolerate TMP/SMX, and cytomegalovirus
(CMV) prophylaxis (when ANC  750/mm3  2 days after transplantation
and donor and/or recipient were CMVþ) with foscarnet 90 mg/kg i.v. every
other day, alternating with ganciclovir 5 mg/kg i.v. every other day until day
100, as we have previously reported [30]. All patients received sargramostim
(250 mg/m2 per day) i.v. daily from day 0 until the white blood cell count
reached  .3  109/L for 2 days and then were switched to ﬁlgrastim (10 mg/
kg per day) either i.v. or subcutaneously until an ANC  2.5  109/L was
achieved for 3 days, as we previously described [31]. Intravenous immune
globulin (IVIG) 200 mg/kg was administered starting on day 1 and
continued every 3 weeks until day þ100. IVIG was discontinued on
day þ100 for patients with < grade II aGVHD. For patients with  grade II
aGVHD on day þ100, treatment was continued until the severity of aGVHD
was < grade II. Patients with IgA deﬁciency were given IVIG products low in
IgA. Patients who developed cGVHD or relapse of greater than or equal to
grade II aGVHD resumed IVIG prophylaxis until severity of aGVHD was less
than grade II.
BAL and Biopsy Procedures
BAL was performed by a pediatric pulmonologist, using an age-adjusted
ﬂexible bronchoscope. Warmed sterile normal saline was instilled in 4 to 6
aliquots of 10 to 20 cc, which was suctioned and sent for pathology and
microbiology evaluation.
LBs were by VATS, OLB, or CT-guided biopsies, at the discretion of the
pediatric HSCT physician and pediatric surgeon. OLBs and VATS were per-
formed by a pediatric surgeon. Further intervention or resection was at the
discretion of the surgeon. CT-guided biopsies were performed by an inter-
ventional radiologist, obtaining ﬁne needle aspiration and core biopsy
samples.
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samples were screened for infectious diseases with Gram, acid fast, Gomori
methenamine silver stains, and viral immunostains. Samples were also
cultured for bacteria, viruses, and fungi. Respiratory syncytial virus,
adenovirus, inﬂuenza A, and parainﬂuenza were speciﬁcally screened with
an ELISA and shell vial culture coupled with immunoﬂuorescence stains.
Flow cytometry was also performed in all patients with leukemia or lym-
phoma. A false-negative BAL was deﬁned as a nondiagnostic BAL that was
followed by an LB or autopsy within 2 weeks of BAL that identiﬁed at least 1
etiology for the patient’s pulmonary dysfunction.Statistical Analysis
BAL and LB were considered to be diagnostic if any etiology for respi-
ratory dysfunction was identiﬁed. We further examined the following var-
iables: age at time of HSCT, gender, disease type (malignant or
nonmalignant), disease risk status, type of transplantation (MAC autoSCT,
RTC alloSCT, or MAC alloSCT), graft source (related or unrelated), HLA
matching, recipient and donor CMV serologic status, graft manipulation
(CD34þ selection), the presence of a primary immune deﬁciency, the use of
T cell antibodies (antithymocyte globulin or alemtuzumab), and presence of
aGVHD and cGVHD before or at the time of BAL or LB. Poor-risk disease was
deﬁned by patients with refractory malignant disease, patients not with
complete response (CR) at the time of HSCT, patients in CR3 or beyond,
patients with history of induction failure, and patients receiving a second
alloSCT. The remainder of patients were classiﬁed as average risk. Adverse
events associated with BAL or LB were also analyzed.
Continuous variables were summarized as mean  standard deviation,
and 2-sided t-tests were used for 2-group comparison. Categorical variables
were summarized as percentages and chi-square tests were used for 2-
group comparison. Kaplan-Meier curves and log-rank tests were used for
comparing time to ﬁrst BAL and time to death between 2 groups. Cox pro-
portional hazards models were used to examine the effect of each covariate
on time to the ﬁrst BAL and time to death. Acute and chronic GVHD status
were considered as time-dependent covariates in the Cox proportional
hazards models. Covariates with P < .2 were included in the ﬁnal multi-
variable Cox proportional hazards model. All statistical analyses were per-
formed with the use of SAS version 9.2 software (SAS Institute, Cary, NC).
The signiﬁcance level was set to be .05.Table 1
Patient Demographics and Characteristics
All Patients (N ¼ 193) BAL Cohort (n ¼ 65)
Age, mean, SD 8.59 (2.26-14.92  6.33) 9.98 (3.42-16.54  6.5
Sex
Male 116 37
Female 77 28
Diagnosis
Malignant 140 44
Nonmalignant 53 21
Risk status
Average risk 152 49
Poor risk 41 16
Transplantation type
MAC autoSCT 38 3
MAC alloSCT 83 45
RTC alloSCT 72 17
Graft
Related 58 24
Unrelated 97 38
HLA match
6/6 or 10/10 54 27
Other mismatch 91 35
T cell antibodyy
R-ATG 88 32
Alemtuzumab 31 12
None 73 20
CMV status
Neg/neg 99 19
Other 94 46
BAL indicates bronchoalveolar lavage; MAC, myeloablative conditioning; autoSCT
plantation; RTC, reduced-toxicity conditioning; R-ATG, rabbit antithymocyte globu
Data presented are n, unless otherwise indicated.
* All but 2 patients in the biopsy cohort are also reﬂected in the BAL group.
y One patient received ATG and alemtuzumab.RESULTS
Patient Demographic and Transplantation
Characteristics
During the study period, 193 patients underwent 235
HSCTs. The majority of sequential transplantation were
either planned tandem triple autologous transplantations in
patients with central nervous system tumors (n ¼ 4), plan-
ned autologous transplantations followed by reduced-in-
tensity allogeneic transplantations in patients with
lymphoma or neuroblastoma (n ¼ 20), graft failure requiring
a second alloSCT (n ¼ 12), or relapse (n ¼ 6). The de-
mographics of the patients and transplantation characteris-
tics are depicted in Table 1. Brieﬂy, themean age of the cohort
was 8.6 years (range, 2.3 to 14.9), the cohort included 116
male and 77 female patients, there were 140 malignant and
53 nonmalignant diagnoses, and therewere 38MAC autoSCT,
83 MAC alloSCT, and 72 RTC alloSCT performed.
Sixty-ﬁve patients (34%) underwent a total of 101 BALs
for fever, respiratory distress, and/or pulmonary in-
ﬁltrate(s) on chest X-ray and/or CT scan. Ninety-ﬁve BALs
(94%) were performed after alloSCT and 6 BAL (6%) were
performed after autoSCT. The median time of BAL after
alloSCT and autoSCT was day þ95 and day þ31, respec-
tively. The 1-year probability of undergoing BAL after HSCT
was 43.0% for alloSCT and 8.5% for autoSCT (P ¼ .001).
Sixteen of the 193 patients (8%) patients underwent 19 LB
for the following indications: nondiagnostic BAL within
30 days, suspected recurrent disease, solitary lung mass/ab-
scess, and obstructive and/or restrictive lung disease. Eleven
(58%) of the LB were surgical LB, consisting of 8 VATs and 3
OLBs, and 8 (42%) were CT-guided biopsies. Two of the 16
patients had not previously undergone a BAL (1 patientBiopsy Cohort* (n ¼ 16) No BAL/Biopsy Cohort (n ¼ 126)
6) 10.63 (3.77-17.59  6.86) 7.84 (1.75-13.93  6.09)
10 77
6 49
13 94
3 32
13 102
3 24
4 34
6 32
6 54
4 34
8 58
3 37
9 55
4 55
3 19
9 52
5 78
11 48
, autologous stem cell transplantation; alloSCT, allogeneic stem cell trans-
lin; CMV, cytomegalovirus; neg, negative.
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rent disease); they are, therefore, not included within the
BAL patient cohort. The probability of undergoing LB at
1 year after HSCT was 9.3%.
The probabilities of developing grades II to IV aGVHD and
cGVHD were 29.5% (n ¼ 57) and 5.7 (n ¼ 11), respectively.
Among patients undergoing BAL or LB, the incidence was
31.3% (n ¼ 21) and 7.5% (n ¼ 5), respectively (P ¼ not
signiﬁcant).
Diagnostic Yield
Of the 101 BALs performed in 65 patients, 40% (n ¼ 40)
were diagnostic. All diagnostic BAL revealed an infectious
etiology, with bacteria being the most prevalent isolated
pathogens (Figure 1A,B). Four BALs identiﬁed 2 microor-
ganisms (Mycobacterium avium complex and vancomycin-
resistant Enterococci [n ¼ 2], coagulase-negative staphylo-
coccus and Pseudomonas aeruginosa [n ¼ 1], and Pseudo-
monas aeruginosa and Candida glabrata [n ¼ 1]) and 3 BAL
identiﬁed 3 pathogens (Enterococcus faecium, Candida albi-
cans, Candida krusei [n ¼ 1]; Staphylococcus epidermidis,
Streptococcus group D, and Candida not otherwise speciﬁed
[n ¼ 1]; and CMV, adenovirus, and parainﬂuenza type 3
[n ¼ 1]). All pathogens isolated from BAL specimens are
described in Table 2.
Overall, no pathogens were detected in 61% (n ¼ 61) of
BALs tested. Among BALs performed in the ﬁrst 30 days after
HSCT, 67% were diagnostically unrevealing (“negative”).
There was no statistically signiﬁcant difference in theFigure 1. (A) Diagnostic yield of bronchoaleolar lavage (BAL) versus lung biopsy (P <
lung biopsy.diagnostic yield of BAL performed within the ﬁrst 30 days
after HSCT compared with after 30 days. Two negative BALs
were followed within 2 weeks by diagnostic BAL (both pos-
itive for CMV). Thirteen negative BALs were followed within
30 days (median, 13 days) by biopsy (n ¼ 7) or autopsy
(n ¼ 6). Of the 7 biopsies, all were diagnostic and 6 (86%)
identiﬁed at least 1 infectious pathogen; 2 biopsies yielded 2
etiologies. Five of the autopsies were diagnostic and 4
identiﬁed at least 1 infectious pathogen. Representative
chest CT scans from patients with falsely negative BAL are
shown in Figure 2A-C. A more detailed representation of the
etiologies identiﬁed by biopsy and autopsy after initial
negative BAL is provided in Table 3. A representative path-
ological sample of a post-HSCT pediatric recipient with a
negative BAL (false-negative) and a positive LB is depicted in
representative pathology specimens in Figure 3A-H. There
was a signiﬁcant increase in diagnostic yield between BAL
versus LB (40% versus 94%, P < .001) (Figure 1A,B).
Among the 19 LB performed, 94% of the biopsies identi-
ﬁed at least 1 etiology: infection (n ¼ 11), ﬁbrosis (n ¼ 4),
GVHD (n ¼ 3), and recurrent malignant disease (n ¼ 1)
(Figure 1A,B). Overall, lung autopsies were performed in a
total of 14 patients (43%). Seven of 14 autopsies (50%) pro-
vided at least 1 pathogen previously unidentiﬁed after a
falsely negative BAL.
Respiratory Status before and after BAL and/or LB
Records regarding ventilatory status surrounding the
time of BAL were available for 88 of 101 cases. Of these cases,.0001). (B) Distribution of diagnosis after bronchoalveolar lavage (BAL) versus
Figure 2. (A) Patient with cytomegalovirus: chest CT with contrast shown in lung wi
small right pleural effusion. Findings suggest diffuse lung disease but are not speciﬁc
chest CT shown in lung windows reveals tree-in-bud opacities posteriorly in the rig
particularly in the right middle lobe and lingula. The appearance and distribution sug
chest CT scan with contrast shown in lung windows reveals ground glass and mild c
Table 2
Pathogen Identiﬁed with BAL
Pathogen n
Bacteria 23
Mycobacterium avium complex 6
Staphylococcus epidermdis 4
Vancomycin-resistant Enterococcus 3
Pseudomonas aeruginosa 3
Coagulase-negative Staphylococcus NOS 2
Legionella sp 1
Serratia marcescens 1
Streptococcus group D 1
Enterococcus faecium 1
Lactobacillus sp 1
Virus 14
CMV 6
Adenovirus 5
Parainﬂuenza 3 2
Inﬂuenza B 1
RSV 1
Fungus 12
Candida NOS 4
Aspergillus fumigatus 2
Candida krusei 2
Candida albicans 1
Candida glabrata 1
Trichosporon ashaii 1
Fungus NOS 1
Other 1
Pneumocystis jirovecii 1
BAL indicates bronchoalveolar lavage; NOS, not otherwise speciﬁed; CMV,
cytomegalovirus; RSV, respiratory syncytial virus.
Data presented are n.
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BAL, and of these cases, 73% (n ¼ 25) were intubated for
respiratory distress before the BAL. The median duration of
intubation was 8.5 days. Of the 19 LBs, 5 patients remained
intubated for > 48 hours after the procedure, 2 of whom had
been intubated before the procedure. Themedian duration of
intubation was 4 days.
Complications and Adverse Events after BAL and/or LB
Eight patients required chest tube placement after OLB,
which was transient and did not progress to grade III toxicity.
One patient developed postoperative seizures, felt to be
unrelated to the OLB. One patient subsequently developed a
grade III hemorrhage after CT-guided LB. This patient was
intubated and died within 48 hours after the procedure; the
biopsy was positive for Aspergillus fumigatas and the death
was considered to be secondary to pulmonary aspergillosis
and unrelated to CT-guided biopsy.
Univariate and Multivariate Analysis on Factors
Associated with BAL
The probability of undergoing BAL was 7.9% for MAC
autoSCT patients, 23.6% for RTC alloSCT patients, and 54.2%
for MAC alloSCT patients, representing a signiﬁcantly higher
probability in the MAC alloSCT group (hazard ratio [HR], 7.4;
95% conﬁdence interval [CI], 2.7% to 20.8%; P < .0001). Other
statistically signiﬁcant factors in the univariate analysis
included age at HSCT, which had a hazard ratio of 1.05 (95%ndows reveals interlobular septal thickening, ground glass opaciﬁcation and a
for 1 entity. (B) Patient with Mycobacterium Avium Intracellulare: noncontrast
ht upper lobe. Similar opacities were seen throughout the lungs (not shown),
gests the presence of M. avium intracellulare. (C) Patient with parainﬂuenza 3:
onﬂuent nodular opacities present posteriorly in the lungs bilaterally.
Figure 3. (A) Lung biopsy section immunostained for herpes simplex virus (HSV)-1.
immunostained for cytomegalovirus (CMV). Positive cells are seen, consistent with CM
virus (HPIV). Positive cells are seen, consistent with parainﬂuenza virus infection. (D
stain, consistent with a mycobacterial infection. (E) Lung tissue section. Fungi (branch
with Gomori methenamine stain (GMS), consistent with Aspergillus infection. (F) Lu
phocytic inﬂammation involving the epithelium and wall of the airway, and rare ap
disease (GVHD), causing obliterative bronchiolitis (constrictive bronchiolitis). (G) Lu
seen, consistent with recurrent classical Hodgkin lymphoma. (H) Lung tissue section
Table 3
Diagnostic Biopsy and Autopsy after Negative BAL
Biopsy n Autopsy n
Infectious Mycobacterium avium complex* 1 Adenovirus 2
CMV 1 CMVþHSV 1
Parainﬂuenzaþinﬂuenza 1 CMV 1
Parainﬂuenza 3 1
HSV-1 1
Aspergillus fumigatus 1
Noninfectious GVHD* 2 Fibrosis 1
BAL indicates bronchoalveolar lavage; CMV, cytomegalovirus; HSV, herpes
simplex virus; GVHD, graft-versus-host disease.
* One biopsy demonstrated GVHD and Mycobactrium avium complex.
E. Qualter et al. / Biol Blood Marrow Transplant 20 (2014) 1229e12371234CI, 1.0 to 1.1; P ¼ .01) and grade II to IV aGVHD (HR, .105; 95%
CI, .01 to .03; P ¼ .027). When controlling for other factors in
multivariate analysis, MAC alloSCT conferred the highest risk
of requiring a BAL (HR, 8.5; 95% CI, 2.7 to 26.3; P ¼ .0002)
(Table 4). In univariate analysis, there were no statistically
signiﬁcant variables in predicting positive, compared with
nondiagnostic, BAL. In the univariate analysis, there were no
statistically signiﬁcant predictors for risk of requiring an LB;
however, the number of patients was small.Survival Analysis
The probability of overall survival was 20.2% in pediatric
HSCT recipients who required BAL, 17.5% in those who un-
derwent a LB, and 67.4% in those who had neither procedureRare cells are positive, consistent with HSV infection. (B) Lung tissue section
V infection. (C). Lung tissue section immunostained for human parainﬂuenza
) Lung tissue section. Numerous acid fast bacilli (AFB) are seen on AFB special
ed, septate hyphae), morphologically compatible with Aspergillus are identiﬁed
ng tissue section. A small airway shows scarring of the wall, associated lym-
optotic debris in the epithelium, consistent with pulmonary graft-versus-host
ng tissue section immunostained for CD30. Multiple large Hodgkin cells are
. On trichrome special stain, diffuse, panlobular interstitial ﬁbrosis is seen.
Table 4
Multivariate Analysis of Predictors of BAL
Variable Hazard Ratio 95% Conﬁdence
Interval
P Value
Age 1.056 1.012-1.101 .0122
Risk
Average Reference (1.0)
Poor 1.427 .802-2.540 .2262
Chronic GVHD .217 .030-1.585 .1321
Acute GVHD .066 .009-.485 .0076
Transplantation type
MAC autoSCT Reference (1.0)
MAC alloSCT 8.464 2.725-26.293 .0002
RTC alloSCT 2.613 .751-9.083 .1309
T cell antibody
None Reference (1.0)
R-ATG .785 .417-1.478 .4531
Alemtuzumab 1.223 .543-2.754 .6270
BAL indicates bronchoalveolar lavage; GVHD, graft-versus-host disease;
MAC, myeloablative conditioning; autoSCT, autologous stem cell trans-
plantation; alloSCT, allogeneic stem cell transplantation; RTC, reduced-
toxicity conditioning; R-ATG, rabbit antithymocyte globulin.
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having a statistically signiﬁcant mortality risk included BAL,
age, disease risk, HLA matching, and transplantation type.
When controlling for other factors in multivariate analysis,
only the requirement of a BAL was independently associated
with an increased risk of mortality after HSCT in pediatric
recipients (HR, 2.96; 95% CI, 1.8 to 4.9; P < .0001). Of patients
with at least 1 positive BAL,10% of patients survived, whereas
in patients with a nondiagnostic BAL, 56% of patients sur-
vived (P < .0001).DISCUSSION
To our knowledge, this study is the largest cohort of
pediatric HSCT recipients analyzing invasive diagnostic
procedures for pulmonary dysfunction to date. The cohort
described is a heterogeneous group, including patients with
differing underlying diseases and conditioning regimens,
including MAC and RTC regimens, as well as both autologous
and allogeneic donor sources. In pediatric patients with
pulmonary complications after HSCT, BAL remains the ﬁrst-
line diagnostic procedure for patients with pulmonary
dysfunction [7]. Our analysis demonstrates that, among our
diverse patient population, the diagnostic yield of BAL was
40%. This is consistent with the diagnostic yield of BAL in
pediatric HSCT recipients described by others in smaller se-
ries, which range from 29% to 68% [7,8].
As expected, the diagnostic yield we observed from LB
was substantially higher (94%) than BAL at 40%, consistent
with the post-HSCT LB diagnostic yield reported by others
[12-14]. In particular, LB greatly increased the yield for
certain disease-speciﬁc diagnoses, including GVHD, pulmo-
nary toxicity, and rare infectious organisms. In a smaller
retrospective study, OLB yielded new information that led to
a change in therapy more often than BAL or CT-guided
biopsy; furthermore, although CT-guided biopsy had a high
diagnostic yield of 60%, the diagnostic value was diminished
by the fact that they yielded only organisms that had already
been isolated from peripheral culture (blood or sputum) [32].
Although the diagnostic yield was higher after LB com-
pared with BAL, the former represents a more invasive pro-
cedure. However, although our sample size is small, we did
not observe grade III or IV toxicities related to LB in our
cohort. Although 34% of BAL patients and 26% of LB patientsrequired intubation after the procedure, it is not possible to
know from this analysis whether these intubations were a
result of the patient’s signiﬁcant underlying pulmonary
disease, a result of the diagnostic procedure (whether BAL or
LB), or a combination of these factors, especially given that
most of these patients had already been intubated because of
respiratory distress before the procedure. Thus, it is impor-
tant to consider the value of the possible diagnostic yield for
these procedures compared with the risks of intubation in
these patients.
Patients undergoing MAC alloSCT were the most likely to
require BAL, and although there are no studies directly
comparing pulmonary complications in children undergoing
MAC versus RTC, this result is not unexpected based on our
previous work [21]. It is important to consider that the pa-
tients at lowest risk forundergoingBALwere theMACautoSCT
group. This suggests that both the conditioning regimen and
graft source are potentially powerful inﬂuences associated
with pulmonary dysfunction and the need for a BAL.
Patients undergoing BAL and LB were observed to have
higher mortality than those who did not. This is most likely
related to the morbidity and mortality involved in their un-
derlyingpulmonarydisease and theymayhave receivedaMAC
AlloSCT. These results are similar to other reports in the liter-
ature [7]. Additionally, it is important to consider that given the
retrospective nature of these studies, it is not possible to know
whether these patients would have increased or decreased
survival without these diagnostic procedures.
As mentioned, 1 of the largest limitations of this study is
its retrospective nature. In addition to the limitations of
retrospective analysis, this includes the fact that the decision
to perform BAL or LB was decided by attending HSCT phy-
sicians in consultation with the consulting pediatric pulmo-
nologist, intensive care physician, surgeon, and radiologist
based on the individual clinical features in each case.
Another potential limitation of this study was the inability to
determine the signiﬁcance of timing of the BAL from clinical
onset versus the percent of successful diagnostic yield. The
standard of care in our HSCT center was to attempt to
perform a diagnostic BAL within 72 hours of onset of clinical
symptoms and CT ﬁndings of bilateral ground glass opacities.
This occurred in over 95% of cases and, therefore, the
numbers were too small to determine whether the timing of
BAL was signiﬁcantly associated with a successful diagnostic
yield from the BAL. The cohort of patients in our study is
quite diversewith respect to underlying disease, graft source,
and conditioning regimen, and although this heterogeneity
can seem to make for a diverse patient group, it may suggest
applicability of the results to a more diverse population of
pediatric HSCT recipients. Additionally, the number of pa-
tients who had autoSCT was quite small, consistent with the
limited use of autoSCT in pediatric diseases.
In summary, we have demonstrated a high diagnostic
yield of approximately 40% for BAL and 94% for LB for the
diagnosis of pulmonary complications in pediatric HSCT re-
cipients. Based on this study, we establish that approxi-
mately 34% and 8% of pediatric HSCT recipients will require a
BAL and LB, respectively, sometime after their HSCT. In our
cohort, both BAL and LB were safe and well tolerated with a
signiﬁcant diagnostic yield. Although BAL is traditionally
considered the initial diagnostic procedure of choice in pe-
diatric HSCT recipients with pulmonary dysfunction of
unclear etiology, LB should be considered as an initial
diagnostic procedure and performed early in certain cir-
cumstances, particularly when GVHD, pulmonary ﬁbrosis,
Figure 4. (A) Probability of overall survival in pediatric HSCT recipients stratiﬁed for patients requiring bronchoalveolar lavage (BAL) versus no BAL/LB. (B) Probability
of overall survival in pediatric HSCT recipients stratiﬁed for patients requiring lung biopsy versus no lung biopsy/bronchoalveolar lavage.
E. Qualter et al. / Biol Blood Marrow Transplant 20 (2014) 1229e12371236treatment toxicity, or atypical infectious organisms are being
considered. Future studies should be performed to improve
the long-term survival in pediatric HSCT recipients with
pulmonary dysfunction who require these types of diag-
nostic procedures.
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